CAPRICOR THERAPEUTICS, INC. (NASDAQ:CAPR) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07.
|
Submission of Matters to a Vote of Security Holders. |
Capricor Therapeutics, Inc. (the Company) held its 2017 Annual
Meeting of Stockholders (the Annual Meeting) on June 14, 2017 at
the Companys principal executive offices located at 8840 Wilshire
Blvd., Beverly Hills, California 90211.At the Annual Meeting, the
Companys stockholders were asked to vote upon the following three
proposals, each of which is described in more detail in the
Companys definitive proxy statement filed with the Securities and
Exchange Commission on April 21, 2017:
| 1. |
The election of seven nominees to the Companys Board of Directors to serve until the 2018 annual meeting of stockholders. The nominees for election were Frank Litvack, M.D., Linda Marbn, Ph.D., David B. Musket, George W. Dunbar, Jr., Louis Manzo, Earl M. (Duke) Collier, Jr. and Joshua Kazam; |
|
| 2. |
The ratification of the appointment by the Audit Committee of the Companys Board of Directors of Rose, Snyder Jacobs LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2017; and |
|
| 3. |
A non-binding advisory vote to approve the compensation of the Companys named executive officers. |
The results of the matters voted on at the Annual Meeting, based
on the presence in person or by proxy of holders of record of
18,185,184 shares of the 21,399,019 shares of the Companys common
stock entitled to vote, were as follows:
| 1. |
The election of each of Dr. Litvack, Dr. Marbn, and Messrs. Musket, Dunbar, Manzo, Collier, and Kazam, as directors of the Company to serve until the 2018 annual meeting of stockholders, and until his or her successor is elected, or until his or her earlier death, resignation or removal, was approved as follows: |
| FOR | WITHHELD | BROKER NON-VOTES | |||
| Frank Litvack, M.D. | 12,075,564 | 387,166 | 5,722,454 | ||
| Linda Marbn, Ph.D. | 12,437,088 | 25,642 | 5,722,454 | ||
| David B. Musket | 12,437,414 | 25,316 | 5,722,454 | ||
| George W. Dunbar, Jr. | 12,430,828 | 31,902 | 5,722,454 | ||
| Louis Manzo | 12,431,414 | 31,316 | 5,722,454 | ||
| Earl M. (Duke) Collier, Jr. | 12,354,629 | 108,101 | 5,722,454 | ||
| Joshua Kazam | 12,395,018 | 67,712 | 5,722,454 |
| 2. |
The ratification of the appointment by the Audit Committee of the Companys Board of Directors of Rose, Snyder Jacobs LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2017 was ratified as follows: |
| FOR | AGAINST | ABSTAIN | BROKER NON-VOTES | ||
| 17,878,792 | 83,134 | 223,258 |
| 3. |
The compensation of the Companys named executive officers was approved, on a non-binding advisory basis, as follows: |
| FOR | AGAINST | ABSTAIN | BROKER NON-VOTES | ||
| 12,331,098 | 81,828 | 49,804 | 5,722,454 |
About CAPRICOR THERAPEUTICS, INC. (NASDAQ:CAPR)
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles.
